The GRADE Studies for Type 2 Diabetes

The GRADE studies evaluated the pharmacotherapy of diabetes after initiation of metformin – for both micro- and macrovascular outcomes. Join host, Geoff Wall, and guest Jake Galdo as they examine these studies to determine if they are GameChangers in diabetes management.The GameChangerInsulin glargine and liraglutide had the biggest decrease in A1c; however, many patients still did not reach goal targets. Minor differences in microvascular and macrovascular outcomes were observed.Show Segments00:00 - Introductions1:40 - The GRADE Studies12:02 - Glycemic Outcomes16:08 - Microvascular and Cardiovascular Outcomes21:10 - The GameChanger: Selecting a Second Medication27:18 - Connecting to Practice: Realistic Diabetes Care33:17 - Closing RemarksHostGeoff Wall, PharmD, BCPS, FCCP, CGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint HealthGuestJohn A Galdo, PharmD, MBA, BCPS, BCGP (Jake)Director, CEimpactPharmacist, Ross Bridge PharmacyCEO, SeguridadReferences and ResourcesGlycemia Reduction in Type 2 Diabetes - Glycemic OutcomesGlycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Redeem your CPE or CME hereCPE (Pharmacist)CME (Physician)Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)Pharmacists: Get a membershipPrescribers: Get a membershipCE InformationLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Select a second medication after metformin in a patient with type 2 diabetes based on the data from the GRADE studies2. Discuss the results of the GRADE studies0.05 CEU/0.5 HrUAN: 0107-0000-22-401-H01-PInitial release date: 10/31/2022Expiration date: 10/31/2023Additional CPE and CME details can be found here.Follow CEimpact on Social Media:LinkedInInstagram